Marknadsnyheter
AstraZeneca advances scientific leadership in haematology at ASH 2023
Calquence six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukaemia, and data across multiple haematology assets showcase breadth of promising early pipeline. New, longer-term data from ALPHA Phase III trial will further show potential of danicopan to address clinically significant extravascular haemolysis and maintain disease control, allowing paroxysmal nocturnal haemoglobinuria patients to continue standard-of-care treatment with Ultomiris or Soliris.
AstraZeneca will present new clinical and real-world data in multiple haematological conditions at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023.
A total of 63 abstracts will feature 14 approved and potential new medicines across the Company’s portfolio and pipeline including from Alexion, AstraZeneca’s Rare Disease group, in chronic lymphocytic leukaemia (CLL) and several types of lymphoma, paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS) and amyloid light-chain (AL) amyloidosis.
Anas Younes, Senior Vice President, Haematology R&D, AstraZeneca, said: “Our data at ASH will exemplify how we are advancing a range of innovative modalities including antibody drug conjugates, next-generation immunotherapies and T-cell engagers in haematology. Updated clinical data for AZD0486, our CD19/CD3 T-cell engager, reinforce our belief in this approach as a potential new treatment for lymphoma, and new Calquence data continue to demonstrate long-term efficacy and safety in chronic lymphocytic leukaemia with further follow up.”
Gianluca Pirozzi, Senior Vice President, Head of Development, Regulatory and Safety, Alexion, said: “Alexion has transformed the treatment landscape and redefined care for the paroxysmal nocturnal haemoglobinuria patient community over the past two decades. At the ASH Annual Meeting, new results from our pivotal ALPHA trial will demonstrate the promise of Factor D inhibition to advance care for the small subset of patients with paroxysmal nocturnal haemoglobinuria who experience clinically significant extravascular haemolysis. We are proud to further our leadership in rare disease by sharing data from our robust haematology pipeline, reflecting our commitment to innovation and improving outcomes for the patients and families we serve.”
Calquence continues to demonstrate long-term benefits in CLL
Six-year follow-up data from the pivotal ELEVATE-TN Phase III trial will further support the continued efficacy, safety and tolerability of Calquence for long-term use in patients with treatment-naïve CLL.1
Data from a Phase II trial will show the safety and efficacy of Calquence and rituximab followed by chemotherapy and autologous stem cell transplantation in fit patients with treatment-naïve mantle cell lymphoma (MCL).2
An analysis of five prospective Calquence trials, including three randomised, controlled Phase III trials and two non-randomised trials, will show acceptable safety outcomes based on rates of nonfatal and fatal ventricular arrhythmias and sudden death in patients with CLL.3
Novel early assets show potential to improve outcomes for blood cancer patients
Data from our early portfolio will demonstrate how the Company is advancing multiple modalities across several scientific platforms, including Immuno-Oncology, Immune-Engagers, Antibody Drug Conjugates (ADCs) and Epigenetics as part of its strategy to attack cancer from multiple angles.
Updated Phase I data for AstraZeneca’s CD19/CD3 T-cell engager, AZD0486, will further demonstrate the acceptable safety profile and high response rate of this treatment in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).4 We will also present the first clinical data on sabestomig, a PD-1/TIM-3 targeting bispecific antibody, in R/R Hodgkin lymphoma, showing encouraging early signals of activity.5
The first preclinical data for AZD9829, a novel CD123-targeting ADC, using AstraZeneca’s proprietary linker technology to deliver a topoisomerase I inhibitor warhead, will demonstrate promising anti-tumour activity in acute myeloid leukaemia.6 In addition, preclinical data will demonstrate anti-tumour activity of AstraZeneca’s novel PRMT5 inhibitor in MTAP silenced Hodgkin lymphoma models.7
Showcasing advances to bolster our leadership in PNH with new data on Factor D inhibition and impact of C5 inhibition in long-term disease control
New results from the 24-week and long-term extension period from the pivotal ALPHA Phase III trial will reinforce the potential for danicopan add-on therapy to address clinically significant extravascular haemolysis (EVH) in the small subset of PNH patients who experience this condition while treated with C5 inhibitor therapy, allowing them to maintain control of intravascular haemolysis (IVH) through standard-of-care treatment with Ultomiris (ravulizumab) or Soliris (eculizumab).8
Further, patient-reported outcomes from the ALPHA trial will suggest danicopan as an add-on to Ultomiris or Soliris improved quality of life compared to C5 inhibitor therapy alone in patients with PNH who experience clinically significant EVH.9
Additionally, Alexion will present an analysis of six-year outcomes from the Phase III clinical trial evaluating the safety and efficacy of Ultomiris in patients with PNH who did not have previous treatment with a C5 inhibitor.10 The analysis compared survival against untreated patients in the International PNH Registry, the largest global real-world database of patients with PNH. Results will suggest Ultomiris improved survival and maintained effective long-term control of IVH, the most significant contributor to morbidity and premature mortality in PNH.10
Improving diagnosis and management of life-threatening rare diseases, including amyloidosis
24-month results of a Phase II trial will demonstrate the safety and tolerability of CAEL-101 in combination with cyclophosphamide-bortezomib-dexamethasone with or without daratumumab for the treatment of AL amyloidosis.11
Real-world analyses across AL amyloidosis, aHUS and haematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will also be presented, advancing the scientific understanding of these rare, haematological conditions.12-16
Key presentations during the 65th ASH Annual Meeting and Exposition
Lead author | Abstract title | Presentation details |
Calquence (acalabrutinib) | ||
Sharman, JP | Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-naive Chronic Lymphocytic Leukemia: 6-year Follow-up of ELEVATE-TN | Abstract # 636 Oral Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia 10 December 2023 17:45 PST Location: Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego) |
Westin, J | Smart Stop: Lenalidomide, Tafasitamab, Rituximab and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-cell Lymphoma | Abstract # 856 Oral Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Initial treatment strategies in Aggressive B-Cell Lymphomas 11 December 2023 15:30 PST Location: Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego) |
Hawkes, EA | A Window Study of Acalabrutinib and Rituximab, Followed by Chemotherapy and Autograft (ASCT) in Fit Patients with Treatment-naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-initiated Australasian Leukaemia and Lymphoma Group NHL33 ‘WAMM’ Trial | Abstract # 735 Oral Session: 623. Mantle Cell, Follicular and Other Indolent B-Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents 11 December 2023 11:00 PST Location: Grand Hall B (Manchester Grand Hyatt San Diego) |
Hawkes, EA | TrAVeRse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment- naïve Mantle Cell Lymphoma | Abstract # 3054 Poster Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomas: Clinical and Epidemiological: Poster II 10 December 2023 18:00 – 20:00 PST Location: Halls G-H (San Diego Convention Center) |
Sharman, J | Analysis of Ventricular Arrhythmias and Sudden Death with Acalabrutinib From 5 Prospective Clinical Trials | Abstract # 4643 Poster Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III 11 December 2023 18:00 – 20:00 PST Location: Halls G-H (San Diego Convention Center) |
Ferrajoli, A | Cumulative Review of Hypertension in Patients with Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies Treated with Acalabrutinib: Data from Clinical Trials | Abstract # 1917 Poster Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I 9 December 2023 17:30 – 19:30 PST Location: Halls G-H (San Diego Convention Center) |
Sun, C | Extended Follow-Up and Resistance Mutations in CLL Patients Treated with Acalabrutinib | Abstract # 1891 Poster Session: 641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I 9 December 202317:30 – 19:30 PST Location: Halls G-H (San Diego Convention Center) |
Jain, P | Acalabrutinib with Rituximab as First-line Therapy for Older Patients with Mantle Cell Lymphoma – A Phase II Clinical Trial | Abstract # 3036 Poster Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomas: Clinical and Epidemiological: Poster II 10 December 2023 18:00 – 20:00 PST Location: Halls G-H (San Diego Convention Center) |
Perini, G | ACRUE: A Phase 2, Open-label Study of Acalabrutinib in Combination with Rituximab in Elderly and/or Frail Patients with Treatment-naïve Diffuse Large B-Cell Lymphoma | e-Publication Online Only |
AZD0486 | ||
Gaballa, S | Double Step-Up Dosing (2SUD) Regimen Mitigates Severe ICANS and CRS While Maintaining a High Efficacy in Subjects with Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase I Trial | Abstract # 1662 Poster Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphomas: Clinical and Epidemiological: Poster I 9 December 2023 17:30 – 19:30 PST Location: Halls G-H (San Diego Convention Center) |
AZD9829 | ||
Dutta, D | First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors | e-Publication Online Only |
AZD7789 | ||
Mei, M | Safety and Preliminary Efficacy of Sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-(L)1 Therapy | Abstract # 4433 Poster Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III 11 December 2023 18:00 – 20:00 PST Location: Halls G-H (San Diego Convention Center) |
PRMT5 inhibitor | ||
Urosevic, J | Epigenetic Silencing of MTAP in Hodgkin’s Lymphoma Renders it Sensitive to a 2nd Generation PRMT5 Inhibitor | Abstract # 4185 Poster Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III 11 December 2023 18:00 – 20:00 PST Location: Halls G-H (San Diego Convention Center) |
Danicopan | ||
Kulasekararaj, A | Danicopan as Add-On Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-term Data | Abstract # 576 Oral Session: 508. Bone Marrow Failure: Acquired: Unraveling the Future of PNH Therapy from Clinical Trials 10 December 2023 17:45 PST Location: Room 7 (San Diego Convention Center) |
Piatek, C | Patient-reported Outcomes: Danicopan as Add-On Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis | Abstract # 1346 Poster Session: 508. Bone Marrow Failure: Acquired: Poster I 9 December 2023 17:30 – 19:30 PST Location: Halls G-H (San Diego Convention Center) |
Ultomiris (ravulizumab) | ||
Kulasekararaj, A | Ravulizumab Provides Durable Control of Intravascular Hemolysis and Improves Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Follow-Up of Study 301 and Comparisons with Patients of the International PNH Registry | Abstract # 2714 Poster Session: 508. Bone Marrow Failure: Acquired: Poster II 10 December 2023 18:00 – 20:00 PST Location: Halls G-H (San Diego Convention Center) |
Röth, A | Ravulizumab Effectiveness in the Real-world: Evidence from the International PNH Registry | Abstract # 2722 Poster Session: 508. Bone Marrow Failure: Acquired: Poster II 10 December 2023 18:00 – 20:00 PST Location: Halls G-H (San Diego Convention Center) |
Piatek, C | Efficacy and Safety of Subcutaneous Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Prior Intravenous Eculizumab: 2-Year Follow-Up | Abstract # 2713 Poster Session: 508. Bone Marrow Failure: Acquired: Poster II 10 December 2023 18:00 – 20:00 PST Location: Halls G-H (San Diego Convention Center) |
CAEL-101 | ||
Valent, J | Safety and Tolerability of CAEL-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study | Abstract # 540 Oral Session: 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis10 December 2023 13:15 PST Location: Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego) |
Costello, M | CAEL-101 Enhances the Clearance of Light Chain Fibrils and Intermediate Aggregates by Phagocytosis | Abstract # 3307 Poster Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II10 December 2023 18:00 – 20:00 PST Location: Halls G-H (San Diego Convention Center) |
AL Amyloidosis | ||
Lyons, G | Treatment Patterns and Outcomes for Patients with Light Chain (AL) Amyloidosis: Analysis of a Large US Claims Database | e-PublicationOnline Only |
Thompson, J | Real-world Treatment Patterns Following Update to National Comprehensive Cancer Network Guidelines for Light-Chain Amyloidosis: Results from a US Administrative Claims Database | e-PublicationOnline Only |
Laires, P | Prevalence, Incidence, and Characterization of Light Chain Amyloidosis in the USA: A Real-world Analysis Utilizing Electronic Health Records (EHR) | e-PublicationOnline Only |
aHUS | ||
Wang, Y | Patient Characteristics and Diagnostic Journey of Thrombotic Microangiopathy Associated with a Trigger: A Real-world, Retrospective, Multi-national Study | e-PublicationOnline Only |
HSCT-TMA | ||
Wang, Y | Real-world Analysis of the Underdiagnosis, Clinical Outcomes and Associated Burden of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA) in the United States of America | Abstract # 491 Oral Session: 904. Outcomes Research – Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders 10 December 2023 10:30 PST Location: Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina) |
PNH | ||
Wagner-Ballon, O | Neutrophil PNH Type II Cells Are Associated with Thrombosis and Bone Marrow Failure Without Hemolysis: Evidence from Analysis of the 5-year French Nation-Wide Multicenter Observational Study | Abstract # 4083 Poster Session: 508. Bone Marrow Failure: Acquired: Poster III 11 December 2023 18:00 – 20:00 PST Location: Halls G-H (San Diego Convention Center) |
Notes
AstraZeneca in haematology
AstraZeneca is pushing the boundaries of science to redefine care in haematology. We have expanded our commitment to patients with haematologic conditions, not only in oncology but also in rare diseases with the acquisition of Alexion, allowing us to reach more patients with high unmet needs. By applying our deep understanding of blood cancers, leveraging our strength in solid tumour oncology and delivering on Alexion’s pioneering legacy in complement science to provide innovative medicines for rare diseases, we are pursuing the end-to-end development of novel therapies designed to target underlying drivers of disease.
By targeting haematologic conditions with high unmet medical needs, we aim to deliver innovative medicines and approaches to improve patient outcomes. Our goal is to help transform the lives of patients living with malignant, rare and other related haematologic diseases, shaped by insights from patients, caregivers and physicians to have the most meaningful impact.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for more than 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
References
- Sharman JP, Egyed M, Jurczak J, et al. Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-naive Chronic Lymphocytic Leukemia: 6-year Follow-up of ELEVATE-TN. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition 2023; 9-12 December 2023; San Diego, California. Abs 636.
- Hawkes EA, Lee ST, Churilov L, et al. A Window Study of Acalabrutinib, Rituximab, Followed by Chemotherapy and Autograft (ASCT) in Fit Patients with Treatment-naïve Mantle Cell Lymphoma (MCL): The Investigator-led Australasian Leukaemia and Lymphoma Group NHL33 ‘WAMM’ Trial. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition 2023; 9-12 December 2023; San Diego, California. Abs 735.
- Sharman JP, Ghia P, Miranda P, et al. Analysis of Ventricular Arrhythmias and Sudden Death with Acalabrutinib From 5 Prospective Clinical Trials. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition 2023; 9-12 December 2023; San Diego, California. Abs 4643.
- Gaballa S, Nair R, Jacobs R, et al. Double step-up dosing (2SUD) Regimen Mitigates Severe ICANS and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-cell Engager (TCE): Updated Safety and Efficacy data from the Ongoing First-in-human (FIH) Phase 1 trial. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition 2023; 9-12 December 2023; San Diego, California. Abs 1662.
- Mei M, Corazzelli G, Morschhauser F, et al. Safety and Preliminary Efficacy of Sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Previously Treated with Anti-PD-(L)1 Therapy. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition 2023; 9-12 December 2023; San Diego, California. Abs 4433.
- Dutta D, Pan P, Fleming R, et al. First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors. Presented at American Society of Hematology (ASH) Annual Meeting and Exposition 2023; 9-12 December 2023; San Diego, California. e-Publication.
- Urosevic J, Lynch JT, Meyer S, et al. Epigenetic Silencing of MTAP in Hodgkin’s Lymphoma Renders it Sensitive to a 2nd Generation PRMT5 Inhibitor. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition 2023; 9-12 December 2023; San Diego, California. Abs 4185.
- Kulasekararaj A, Griffin M, Piatek CI, et al. Danicopan as Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-term Data. Presented at: American Society of Hematology (ASH) Congress; 9-12 December 2023; San Diego, CA. Abs 576.
- Piatek C, Lee JW, Griffin M, et al. Patient-Reported Outcomes: Danicopan as Add-On Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis. Presented at: American Society of Hematology (ASH) Congress; 9-12 December 2023; San Diego, CA. Abs 1346.
- Kulasekararaj A, Schrezenmeier H, Usuki K, et al. Ravulizumab Provides Durable Control of Intravascular Hemolysis and Improves Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-term Follow-up of Study 301 and Comparisons with Patients of the International PNH Registry. Presented at: American Society of Hematology (ASH) Congress; 9-12 December 2023; San Diego, CA. Abs 2714.
- Valent J, Liedtke M, Zonder JA, et al. Safety and Tolerability of CAEL-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study. Presented at: American Society of Hematology (ASH) Congress; 9-12 December 2023; San Diego, CA. Abs 540.
- Lyons G, et al. Treatment Patterns and Outcomes for Patients with Light Chain (AL) Amyloidosis: Analysis of a Large US Claims Database. Presented at: American Society of Hematology (ASH) Congress; 9-12 December 2023; San Diego, CA.
- Thompson J, et al. Real-world Treatment Patterns Following Update to National Comprehensive Cancer Network Guidelines for Light-Chain Amyloidosis: Results from a US Administrative Claims Database. Presented at: American Society of Hematology (ASH) Congress; 9-12 December 2023; San Diego, CA.
- Laires P, et al. Prevalence, Incidence, and Characterization of Light Chain Amyloidosis in the USA: A Real-world Analysis Utilizing Electronic Health Records (EHR). Presented at: American Society of Hematology (ASH) Congress; 9-12 December, 2023; San Diego, CA.
- Wang Y, et al. Patient Characteristics and Diagnostic Journey of Thrombotic Microangiopathy Associated with a Trigger: A Real-world, Retrospective, Multi-National Study. Presented at: American Society of Hematology (ASH) Congress; 9-12 December 2023; San Diego, CA.
- Wang Y, Rava A, Smuzynski M, et al. Real-world Analysis of the Underdiagnosis, Clinical Outcomes and Associated Burden of Hematopoietic Stem Cell Transplantation-associated Thrombotic Microangiopathy (HSCT-TMA) in the United States of America. Presented at: American Society of Hematology (ASH) Congress; 9-12 December 2023; San Diego, CA. Abs 491.
Marknadsnyheter
Sveriges Radios dokumentär ”Agenterna” vann Prix Europa
Radio- och tv-priset Prix Europa delar varje år ut priser till de bästa produktionerna runt om i Europa från public service. Vid galan i Berlin ikväll vann P1 Dokumentär och Ekots dokumentärserie Agenterna priset i klassen ljuddokumentär och Drama för Ungas dramatisering av Mio Min Mio fick ett hedersomnämnande i kategorin för ljuddrama.
Daniel Öhman vid Prix Europa 2024. Foto: Cilla Benkö/Sveriges Radio
– Vi är väldigt glada att den här viktiga granskningen vann. Trots att svenska myndigheter och regeringen gjorde sitt bästa lyckades vi avslöja Irans misstänkta planer att mörda svenska judar och de svenska misstag som gjorde det möjligt. Det här priset visar att fler anser att vi aldrig får låta en auktoritär regim komma undan med att planera terrorattentat utan att allmänheten får veta vad som hänt, säger Daniel Öhman, reporter på Ekot som tog emot priset i Berlin.
– Fantastiskt roligt att den viktiga granskningen ”Agenterna” av Daniel Öhman, Emelie Rosén och Ylva Lindgren hyllas ikväll. Det är ett viktigt avslöjande som berättas på ett fängslande vis. De är alla mycket värdiga vinnare, säger Cilla Benkö, vd på Sveriges Radio.
I Prix Europa delas det ut ett hedersomnämnande i varje klass, i klassen drama blev detta Drama för Unga:s produktion av Mio Min Mio.
– Bredden i vårt utbud visas också med det hedersomnämnande som Drama för Unga fick ikväll för den utmärkta dramatiseringen av Astrid Lindgrens klassiker ”Mio Min Mio”, ett välförtjänt erkännande, säger Cilla Benkö.
Totalt har Prix Europa mottagit 646 bidrag från 31 länder. Priset delades ut vid avslutningsceremonin för Prix Europa i stadshuset, Rotes Rathaus, i Berlin.
Allt innehåll finns tillgängligt i appen Sveriges Radio Play eller via Sveriges Radios hemsida.
Kategori: Audio Investigation
Vinnare
P1 Dokumentär/Ekot: Agenterna
av: Emelie Rosén och Daniel Öhman, producent: Ylva Lindgren
Kategori: Audio Fiction
Hedersomnämnande
Drama för Unga: Mio Min Mio
av: Daniel Karlsson, Eva Staaf, Frida Derwinger, Marie Wennersten och Nasrin Mohamoud
Pressbilder
Daniel Öhman tar emot Prix Europa för Agenterna
(Foto: Cilla Benkö/Sveriges Radio)
Daniel Öhman med Prix Europa
(Foto: Noora Holm/Sveriges Radio)
Läs mer om Prix Europa och se alla vinnare på Prix Europas hemsida
Presskontakt: Claes Bertilson, 070-327 7807 eller claes.bertilson@sverigesradio.se
Marknadsnyheter
Nidhogg Resources Holding AB:s (f.d. Eurocine Vaccines AB) aktie återförs till Spotlights ordinarie lista
Nidhogg Resources Holding AB (f.d. Eurocine Vaccines AB), ”Bolaget” eller ”Nidhogg”, återförs till ordinarie lista. Bolagets aktie har handlats på Spotlights observationslista sedan 15 juni 2023 efter att ha genomfört ett omvänt förvärv av Nidhogg Resources AB och därmed genomgått en ny noteringsprövning. Utöver detta har bolaget bytt namn från Eurocine Vaccines AB till Nidhogg Resources Holding AB. Bolaget har nu blivit godkända för åternotering av Bolagets aktier på Spotlight Stock Markets ordinarie lista.
Nidhogg Resources Holding AB (f.d. Eurocine Vaccines AB) har sedan grundandet 1999 varit inriktat på utveckling av olika vacciner. Denna verksamhet avvecklades under våren 2024. I maj 2024 beslutade Bolaget att genomföra det omvända förvärvet av Nidhogg Resources AB vilket förändrade ägarbilden i Bolaget och en ny styrelse tillkom, samtidigt som verksamheten förändrades. Bolaget har efter det genomgått en ny noteringsprövning som nu har godkänts. Idag är Bolaget ett holdingbolag i syfte att genom dotterbolag bedriva mineral-prospektering och utvinning av basmetaller, ädelmetaller, jordartsmetaller, olje- och gasprospektering, samt utvinning av vätgas i Sverige.
I samband med det omvända förvärvet av Nidhogg Resources AB erhöll de som var aktieägare i Eurocine Vaccines AB vid förvärvet en vederlagsfri teckningsoption av serie TO 6 för varje innehavd aktie. Syftet med teckningsoptionerna är att stärka rörelsekapitalet i Bolaget samt påbörja provbrytning.
Återföring till Spotlights ordinarie lista
Bolaget har efter det genomförda omvända förvärvet av Nidhogg Resources AB samt byte av namn till Nidhogg Resources Holding AB genomgått en ny noteringsprövning. Bolaget är nu godkända och har i samband med det samt inför första teckningsdag av TO 6 upprättat ett memorandum som beskriver Bolagets nya verksamhetsinriktning. Bolagets instrument återförs till Spotlights ordinarie lista från och med den 14 oktober 2024.
Aktie
Kortnamn: NIDHOG
ISIN: SE0015382155
TO 6
Kortnamn: NIDHOG TO 6
ISIN: SE0022421871
Bolagets memorandum kommer inom kort att finnas tillgängligt på www.spotlightstockmarket.com.
För mer information, vänligen kontakta:
Stina Larsson
Head of Listings, Spotlight Stock Market
Marknadsnyheter
Fantasma Games AB (publ) ansöker om avnotering
Den 18 september 2024 offentliggjorde EveryMatrix Software Limited (”EveryMatrix”) ett offentligt uppköpserbjudande till aktieägarna i Fantasma Games AB (publ) (”Fantasma” eller ”Bolaget”) att överlåta samtliga sina aktier i Bolaget till EveryMatrix (”Erbjudandet”). Den 11 oktober 2024 offentliggjorde EveryMatrix att Erbjudandet har accepterats i sådan utsträckning att EveryMatrix efter settlement i Erbjudandet kommer att bli ägare till mer än 90 procent av aktierna i Bolaget samt att samtliga villkor för fullföljande av Erbjudandet har uppfyllts och att EveryMatrix fullföljer Erbjudandet. EveryMatrix offentliggjorde även sin avsikt att påkalla tvångsinlösen avseende resterande aktier i Fantasma som inte lämnats in i Erbjudandet.
Fantasmas styrelse har på begäran av EveryMatrix beslutat att ansöka om avnotering av Fantasmas aktier från Nasdaq First North Growth Market, villkorat av att settlement sker i Erbjudandet på ett sådant sätt att EveryMatrix blir ägare till mer än 90 procent av aktierna i Bolaget och att EveryMatrix påkallar tvångsinlösen av minoritetsaktier i Bolaget. Sista dag för handel i Fantasmas aktier på Nasdaq First North Growth Market kommer att meddelas så snart Fantasma fått information därom från Nasdaq.
Stockholm den 11 oktober 2024
Fantasma Games AB (publ)
Styrelsen
_____
Fredrik Johansson, VD
Tel: +46 73 023 23 29
Epost: fredrik@fantasmagames.com
_____
Om Fantasma Games AB (publ)
Fantasma Games, listat på Nasdaq First North, är en spelstudio baserad i Stockholm som grundades 2016. Företaget har som mål att utveckla högkvalitativa spel och bär en vision om att skapa ”slots beyond gambling”. Den kontinuerligt växande spelportfölj inkluderar bland annat spel som Gold Pigger, Promethues: Titan of Fire, Fortune Llama, Heroes Hunt Megaways™, Hades: River of Souls och Medallion, vilka alla har blivit mycket uppskattade av spelare världen över. Idag är våra spel tillgängliga via över 250 operatörer, inklusive välkända namn som BetMGM, DraftKings, LeoVegas, Paddy Power och Betsson.
_____
Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 11 oktober 2024 klockan 14 (CEST)
-
Analys från DailyFX9 år ago
EUR/USD Flirts with Monthly Close Under 30 Year Trendline
-
Marknadsnyheter2 år ago
Upptäck de bästa verktygen för att analysera Bitcoin!
-
Marknadsnyheter4 år ago
BrainCool AB (publ): erhåller bidrag (grant) om 0,9 MSEK från Vinnova för bolagets projekt inom behandling av covid-19 patienter med hög feber
-
Analys från DailyFX11 år ago
Japanese Yen Breakout or Fakeout? ZAR/JPY May Provide the Answer
-
Analys från DailyFX11 år ago
Price & Time: Key Levels to Watch in the Aftermath of NFP
-
Analys från DailyFX7 år ago
Gold Prices Falter at Resistance: Is the Bullish Run Finished?
-
Marknadsnyheter1 år ago
Därför föredrar svenska spelare att spela via mobiltelefonen
-
Nyheter6 år ago
Teknisk analys med Martin Hallström och Nils Brobacke